相关实验视频
Updated: Jan 15, 2026

02:26
Intracranial Pharmacotherapy and Pain Assays in Rodents
Published on: April 9, 2019
5.8K
针对内体中的蛋白酶激活受体2的纳米药物提供持续的止痛作用
Shavonne L Teng1,2, Rocco Latorre1,2, Divya Bhansali3
1Department of Molecular Pathobiology, College of Dentistry, New York University, New York, NY 10010.
概括
纳米颗粒提供药物来对抗细胞内蛋白酶激活受体2 (PAR2) 信号,有效缓解疼痛并使临床前模型中的行为正常化. 这种纳米医学的方法显示了通过向G蛋白结合受体 (GPCRs) 来治疗各种疾病的前景.
科学领域:
- 药理学和药物输送 药理学和药物输送
- 分子和细胞生物学分子和细胞生物学
- 神经科学是一个神经科学.
背景情况:
- 内部化G蛋白合受体 (GPCRs) 的信号传递机制仍然不清楚,因为测量有机细胞特异信号的挑战.
- 针对细胞内GPCR进行治疗干预是很困难的,因为缺乏选择性抗体的细胞内区间.
研究的目的:
- 通过使用遗传编码生物传感器,研究蛋白酶激活受体2 (PAR2) 的细分信号传递.
- 开发和评估纳米粒子 (NP) 以有针对性地将PAR2抗剂输送到细胞内.
- 在临床前模型中评估细胞内PAR2对抗剂在缓解疼痛方面的治疗潜力.
主要方法:
- 基因编码的生物传感器准了血和早期内,以测量PAR2信号.
- 光纳米粒子 (树脂和聚合物) 被合成,特征为内体积累,并加载了PAR2抗剂 (AZ3451).
- 实验室和体内研究在细胞系,初级细胞和炎症性肠道疾病的小鼠模型中进行.
主要成果:
- PAR2激动剂诱导了早期内基因组的持续信号,激活了包括ERK在细胞质和细胞核中的下游通路.
- 纳米颗粒有效地积聚在各种细胞类型的内体中,包括神经元和上皮细胞,并输送AZ3451.1.
- 在NP封装的AZ3451有效地逆转了细胞内PAR2信号,并在临床前模型中提供了长期的止痛作用.
结论:
- 细胞内PAR2信号传递在内分体中介于疼痛,其对抗性提供了一个可行的治疗策略.
- 通过纳米颗粒介导的PAR2抗剂到内体提供有效和长期的疼痛缓解.
- 这种纳米医疗方法可能会提高GPCR抗剂在治疗各种疾病中的疗效.
相关概念视频
Analgesia and Pain Management
1.5K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.5K
Opioid Analgesics: Synthetic and Semisynthetic Opioids
914
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
914
Opioid Receptors: Overview
4.0K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
4.0K
Nociception
33.0K
Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain.
33.0K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
583
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
583

